Different forms of cardiomyocyte death in post-myocardial infarction ventricular remodeling: mechanisms and therapeutic strategies - Takeaways - MDSpire

Different forms of cardiomyocyte death in post-myocardial infarction ventricular remodeling: mechanisms and therapeutic strategies

  • By

  • Zhixin Wang

  • Feng Zhang

  • Shilong Cao

  • Xinyu Xue

  • Hanbing Li

  • Qian Liu

  • Dong Wang

  • Yuting Wu

  • June 24, 2026

  • 0 min

Share

  • 1

    Myocardial infarction is a leading cause of heart failure and cardiovascular mortality, with ventricular remodeling being a key mechanism in this progression.

  • 2

    Cardiomyocytes undergo various forms of death after myocardial infarction, including necrosis, apoptosis, ferroptosis, and pyroptosis, contributing to ventricular remodeling.

  • 3

    Ferroptosis is characterized by iron-dependent lipid peroxidation and is elevated after ischemia-reperfusion injury, worsening ventricular wall thinning.

  • 4

    Pyroptosis activates the NLRP3/caspase-1/GSDMD pathway, releasing inflammatory cytokines that promote myocardial fibrosis and worsen cardiac function.

  • 5

    Understanding the mechanisms of different cardiomyocyte death forms is crucial for developing targeted therapies to improve outcomes after myocardial infarction.

Original Source(s)

Different forms of cardiomyocyte death in post-myocardial infarction ventricular remodeling: mechanisms and therapeutic strategies

  • by Zhixin Wang, Feng Zhang, Shilong Cao, Xinyu Xue, Hanbing Li, Qian Liu, Dong Wang, Yuting Wu

  • June 24, 2026

Related Content

Immune complex handling in transplantation: central roles for complement factor H, animal models, and translational implications

Long-term outcome of patients with atrial fibrillation and heart failure with preserved ejection fraction after combined radiofrequency catheter ablation and left atrial appendage closure

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.